Micrometastatic disease in breast cancer: Clinical implications

European Journal of Cancer

Volumn 44, Issue 18, 2008, Pages 2726-2736

  Ignatiadis, Michail ^a   Georgoulias, Vassilis ^b,c   Mavroudis, Dimitris ^b,c  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Breast cancer; Circulating tumour cells; CK19mRNA; Disseminated tumour cells; Immunocytochemistry; Micrometastatic cells; Prediction; Prognosis; RT PCR

Indexed keywords

AROMATASE INHIBITOR; CYTOKERATIN 19; MESSENGER RNA; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CIRCULATING TUMOR CELL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISSEMINATED TUMOR CELL; DNA FINGERPRINTING; FLOW CYTOMETRY; GENOTYPE; HORMONAL THERAPY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; MICROMETASTASIS; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 56849116263     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.09.033     Document Type: Article

References (110)

1. Carter C.L., Allen C., and Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63 (1989) 181-187
2. Diel I.J., Kaufmann M., Costa S.D., et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88 (1996) 1652-1658
3. Braun S., Pantel K., Muller P., et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342 (2000) 525-533
4. Braun S., Vogl F.D., Naume B., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353 (2005) 793-802
5. Stathopoulou A., Vlachonikolis I., Mavroudis D., et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20 (2002) 3404-3412
6. Xenidis N., Perraki M., Kafousi M., et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24 (2006) 3756-3762
7. Ignatiadis M., Xenidis N., Perraki M., et al. Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early breast cancer. J Clin Oncol 25 (2007) 5194-5202
8. Husemann Y., Geigl J.B., Schubert F., et al. Systemic spread is an early step in breast cancer. Cancer Cell 13 (2008) 58-68
9. Schardt J.A., Meyer M., Hartmann C.H., et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8 (2005) 227-239
10. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 (2007) 5287-5312
11. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20 (2002) 3628-3636
12. Klein C.A., Schmidt-Kittler O., Schardt J.A., Pantel K., Speicher M.R., and Riethmuller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA 96 (1999) 4494-4499
13. Klein C.A., Blankenstein T.J., Schmidt-Kittler O., et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360 (2002) 683-689
14. Fehm T., Sagalowsky A., Clifford E., et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 8 (2002) 2073-2084
15. Slade M.J., and Coombes R.C. The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol 4 (2007) 30-41
16. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13 (2006) 1033-1067
17. Pantel K., and Brakenhoff R.H. Dissecting the metastatic cascade. Nat Rev Cancer 4 (2004) 448-456
18. Ignatiadis M., Georgoulias V., and Mavroudis D. Circulating tumor cells in breast cancer. Curr Opin Obstet Gynecol 20 (2008) 55-60
19. Pantel K., Brakenhoff R.H., and Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8 (2008) 329-340
20. Hayes D.F., and Smerage J. Is there a role for circulating tumor cells in the management of breast cancer?. Clin Cancer Res 14 (2008) 3646-3650
21. Ring A.E., Zabaglo L., Ormerod M.G., Smith I.E., and Dowsett M. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 92 (2005) 906-912
22. Smith B.M., Slade M.J., English J., et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 18 (2000) 1432-1439
23. Kagan M., Howard D., Bendele T., et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 25 (2002) 104-110
24. Krivacic R.T., Ladanyi A., Curry D.N., et al. A rare-cell detector for cancer. Proc Natl Acad Sci USA 101 (2004) 10501-10504
25. Pachmann K., Clement J.H., Schneider C.P., et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 43 (2005) 617-627
26. Nagrath S., Sequist L.V., Maheswaran S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450 (2007) 1235-1239
27. Pantel K., Cote R.J., and Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91 (1999) 1113-1124
28. Jung R., Kruger W., Hosch S., et al. Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br J Cancer 78 (1998) 1194-1198
29. Ring A., Smith I.E., and Dowsett M. Circulating tumour cells in breast cancer. Lancet Oncol 5 (2004) 79-88
30. Zippelius A., Kufer P., Honold G., et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 15 (1997) 2701-2708
31. Kowalewska M., Chechlinska M., Markowicz S., Kober P., and Nowak R. The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. Eur J Cancer 42 (2006) 2671-2674
32. Stathopoulou A., Ntoulia M., Perraki M., et al. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int J Cancer 119 (2006) 1654-1659
33. Reinholz M.M., Nibbe A., Jonart L.M., et al. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res 11 (2005) 3722-3732
34. Chen C.C., Hou M.F., Wang J.Y., et al. Simultaneous detection of multiple mRNA markers CK19, CEA, c-Met, Her2/neu and hMAM with membrane array, an innovative technique with a great potential for breast cancer diagnosis. Cancer Lett 240 (2006) 279-288
35. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351 (2004) 781-791
36. Budd G.T., Cristofanilli M., Ellis M.J., et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 12 (2006) 6403-6409
37. Wong N.S., Kahn H.J., Zhang L., et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat 99 (2006) 63-69
38. Bosma A.J., Weigelt B., Lambrechts A.C., et al. Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 8 (2002) 1871-1877
39. Baker M.K., Mikhitarian K., Osta W., et al. Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clin Cancer Res 9 (2003) 4865-4871
40. Bidard F.C., Vincent-Salomon A., Sigal-Zafrani B., et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 19 (2008) 496-500
41. Soria J.C., Gauthier L.R., Raymond E., et al. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res 5 (1999) 971-975
42. Cote R.J., Rosen P.P., Lesser M.L., Old L.J., and Osborne M.P. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9 (1991) 1749-1756
43. Mansi J.L., Gogas H., Bliss J.M., Gazet J.C., Berger U., and Coombes R.C. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 354 (1999) 197-202
44. Funke I., and Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 16 (1998) 557-566
45. Gebauer G., Fehm T., Merkle E., Jaeger W., and Mitze M. Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients - prognostic relevance after 10 years. Anticancer Res 23 (2003) 4319-4324
46. Gerber B., Krause A., Muller H., et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 19 (2001) 960-971
47. Landys K., Persson S., Kovarik J., Hultborn R., and Holmberg E. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res Treat 49 (1998) 27-33
48. Bidard F.C., Vincent-Salomon A., Gomme S., et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 14 (2008) 3306-3311
49. Janni W., Rack B., Schindlbeck C., et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103 (2005) 884-891
50. Stathopoulou A., Gizi A., Perraki M., et al. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin Cancer Res 9 (2003) 5145-5151
51. Xenidis N., Apostolaki S., Perraki M., et al. Circulating CK-19 mRNA (+) cells in patients with stage I and II breast cancer after the completion of adjuvant chemotherapy: evaluation of their prognostic relevance. Breast Cancer Res Treat 106 Suppl. 1 (2007) [abstract 109]
52. Kahn H.J., Yang L.Y., Blondal J., et al. RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters. Breast Cancer Res Treat 60 (2000) 143-151
53. Witzig T.E., Bossy B., Kimlinger T., et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 8 (2002) 1085-1091
54. Rack B., Schindlbeck C., Schneeweiss A., et al. Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: the German SUCCESS-Trial. Proc Am Soc Clin Oncol (2008) 26 [abstract 503]
55. Pachmann K., Camara O., Kavallaris A., et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 26 (2008) 1208-1215
56. Brabletz T., Jung A., Spaderna S., Hlubek F., and Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5 (2005) 744-749
57. Guirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7 (2007) 834-846
58. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
59. Ignatiadis M., and Desmedt C. Predicting risk of breast cancer recurrence using gene-expression profiling. Pharmacogenomics 8 (2007) 101-111
60. De Cremoux P., Extra J.M., Denis M.G., et al. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res 6 (2000) 3117-3122
61. Zach O., Kasparu H., Krieger O., Hehenwarter W., Girschikofsky M., and Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 17 (1999) 2015-2019
62. Zach O., Kasparu H., Wagner H., Krieger O., and Lutz D. Prognostic value of tumour cell detection in peripheral blood of breast cancer patients. Acta Med Austriaca Suppl 59 (2002) 32-34
63. Silva A.L., Tome M.J., Correia A.E., and Passos-Coelho J.L. Human mammaglobin RT-PCR assay for detection of occult breast cancer cells in hematopoietic products. Ann Oncol 13 (2002) 422-429
64. Ntoulia M., Stathopoulou A., Ignatiadis M., et al. Detection of mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem 39 (2006) 879-887
65. Stathopoulou A., Mavroudis D., Perraki M., et al. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res 23 (2003) 1883-1890
66. Brandt B., Roetger A., Heidl S., et al. Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer 76 (1998) 824-828
67. Apostolaki S., Perraki M., Pallis A., et al. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 18 (2007) 851-858
68. Silva H.A., Abraul E., Raimundo D., et al. Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients. Eur J Cancer 42 (2006) 2617-2622
69. Solomayer E.F., Diel I.J., Meyberg G.C., et al. Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Breast Cancer Res Treat 49 (1998) 145-154
70. Braun S., Schlimok G., Heumos I., et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61 (2001) 1890-1895
71. Solomayer E.F., Becker S., Pergola-Becker G., et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 98 (2006) 179-184
72. Wulfing P., Borchard J., Buerger H., et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12 (2006) 1715-1720
73. Ignatiadis M., Perraki M., Apostolaki S., et al. Molecular detection and prognostic value of circulating CK-19 mRNA- and HER2 mRNA-positive cells in the peripheral blood of women with early breast cancer. Clin Breast Cancer 7 (2007) 883-889
74. Taback B., Chan A.D., Kuo C.T., et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res 61 (2001) 8845-8850
75. Zehentner B.K., Secrist H., Hayes D.C., et al. Detection of circulating tumor cells in peripheral blood of breast cancer patients during or after therapy using a multigene real-time RT-PCR assay. Mol Diagn Ther 10 (2006) 41-47
76. Ignatiadis M., Kallergi G., Ntoulia M., et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 14 (2008) 2593-2600
77. Mikhitarian K., Martin R.H., Ruppel M.B., et al. Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: interim results of a prospective cohort study. BMC Cancer 8 (2008) 55
78. Solakoglu O., Maierhofer C., Lahr G., et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA 99 (2002) 2246-2251
79. Pierga J.Y., Bonneton C., Magdelenat H., et al. Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. Br J Cancer 89 (2003) 539-545
80. Alix-Panabieres C., Vendrell J.P., Pelle O., et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 53 (2007) 537-539
81. Fehm T., Becker S., Becker-Pergola G., et al. Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res 8 (2006) R60
82. Al-Hajj M., Wicha M.S., ito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100 (2003) 3983-3988
83. Balic M., Lin H., Young L., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12 (2006) 5615-5621
84. Theodoropoulos PA, Polioudaki E, Sanidas E, Agelaki S, Mavroudis D, Georgoulias V. Detection of circulating tumor cells with breast cancer stem cell-like phenotype in blood samples of patients with breast cancer. AACR Annual Meeting 2008 [abstract 2008].
85. Wiedswang G., Borgen E., Schirmer C., et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 118 (2006) 2013-2019
86. Pierga J.Y., Bonneton C., Vincent-Salomon A., et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 10 (2004) 1392-1400
87. Benoy I.H., Elst H., Philips M., et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 94 (2006) 672-680
88. Sotiriou C., and Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 7 (2007) 545-553
89. Meng S., Tripathy D., Shete S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101 (2004) 9393-9398
90. Meng S., Tripathy D., Shete S., et al. UPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103 (2006) 17361-17365
91. Kallergi G., Mavroudis D., Georgoulias V., and Stournaras C. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 13 (2007) 79-88
92. Smirnov D.A., Zweitzig D.R., Foulk B.W., et al. Global gene expression profiling of circulating tumor cells. Cancer Res 65 (2005) 4993-4997
93. Hartmann C.H., and Klein C.A. Gene expression profiling of single cells on large-scale oligonucleotide arrays. Nucleic Acids Res 34 (2006) e143
94. Maheswaran S., Sequist L.V., Nagrath S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359 (2008) 366-377
95. Xenidis N., Mavroudis D., Apostolaki S., et al. Effect of adjuvant treatment on the circulating CK19mRNA positive tumor cells in patients with early stage breast cancer. Proc Am Soc Clin Oncol 24 18S (2006) [abstract 20012]
96. Braun S., Kentenich C., Janni W., et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18 (2000) 80-86
97. Xenidis N., Vlachonikolis I., Mavroudis D., et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14 (2003) 849-855
98. Becker S., Solomayer E., Becker-Pergola G., Wallwiener D., and Fehm T. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat 106 (2007) 239-243
99. Slade M.J., Singh A., Smith B.M., et al. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer 114 (2005) 94-100
100. Pantel K., Schlimok G., Braun S., et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85 (1993) 1419-1424
101. Xenidis N., Markos V., Apostolaki S., et al. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 18 (2007) 1623-1631
102. Braun S., Hepp F., Kentenich C.R., et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 5 (1999) 3999-4004
103. Kirchner E.M., Gerhards R., and Voigtmann R. Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells. Ann Oncol 13 (2002) 1044-1048
104. Bozionellou V., Mavroudis D., Perraki M., et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 10 (2004) 8185-8194
105. Barok M., Balazs M., Nagy P., et al. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett 260 (2008) 198-208
106. Borgen E., Naume B., Nesland J.M., et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1 (1999) 377-388
107. Fehm T., Solomayer E.F., Meng S., et al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 7 (2005) 171-185
108. Fehm T., Braun S., Muller V., et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107 (2006) 885-892
109. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., and Clark G.M. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23 (2005) 9067-9072
110. Henry N.L., and Hayes D.F. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 11 (2006) 541-552